Oral azithromycin versus doxycycline in meibomian gland dysfunction: A randomised double-masked open-label clinical trial

British Journal of Ophthalmology

Volumn 99, Issue 2, 2015, Pages 199-204

  Kashkouli, Mohsen Bahmani ^a   Fazel, Ali Jalili ^a   Kiavash, Victoria ^a   Nojomi, Marzieh ^b   Ghiasian, Leila ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL TEAR; AZITHROMYCIN; DOXYCYCLINE; ANTIINFECTIVE AGENT;

ABDOMINAL CRAMP; ADULT; ARTICLE; ARTIFICIAL EYE CLEANING; CONJUNCTIVAL HYPEREMIA; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MEIBOMIAN GLAND DYSFUNCTION; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; COMPARATIVE STUDY; DRUG EFFECTS; EYELID DISEASES; LACRIMAL FLUID; MEIBOMIAN GLAND; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; DOUBLE-BLIND METHOD; DOXYCYCLINE; EYELID DISEASES; FEMALE; HUMANS; LUBRICANT EYE DROPS; MALE; MEIBOMIAN GLANDS; MIDDLE AGED; TEARS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84921615157     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2014-305410     Document Type: Article

References (24)

1. Arita R, Suehiro J, Haraguchi T, et al. Topical diquafosol for patients with obstructive meibomian gland dysfunction. Br J Ophthalmol 2013;97:725-9.
2. Ding J, Kam WR, Dieckow J, et al. The in fluence of 13-cis retinoic acid on human meibomian gland epithelial cells. Invest Ophthalmol Vis Sci 2013;54:4341-50.
3. Prabhasawat P, Tesavibul N, Mahawong W. A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction. Cornea 2012;31:1386-93.
4. Bruce Jackson W. Blepharitis: current strategies for diagnosis and management. Can J Ophthalmol 2008;43:170-9.
5. Guillon M, Maissa C, Wong S. Symptomatic relief associated with eyelid hygiene in anterior blepharitis and MGD. Eye Contact Lens 2012;38:306-12.
6. Lee H, Min K, Kim EK, et al. Minocycline controls clinical outcomes and inflammatory cytokines in moderate and severe meibomian gland dysfunction. Am J Ophthalmol 2012;154:949-57.
7. Akyol-Salman I, Azizi S, Mumcu U, et al. Efficacy of topical N-acetylcysteine in the treatment of meibomian gland dysfunction. J Ocul Pharmacol Ther 2010;26:329-33.
8. Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea 2006;25:171-5.
9. Tomlinson A, Bron AJ, Korb DR, et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci 2011;52:2006-49.
10. Romero JM, Biser SA, Perry HD, et al. Conservative treatment of meibomian gland dysfunction. Eye Contact Lens 2004;30:14-19.
11. Guillon M, Maissa C, Wong S. Eyelid margin modification associated with eyelid hygiene in anterior blepharitis and meibomian gland dysfunction. Eye Contact Lens 2012;38:319-25.
12. Igami TZ, Holzchuh R, Osaki TH, et al. Oral azithromycin for treatment of posterior blepharitis. Cornea 2011;30:1145-9.
13. Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci 2011;52:2050-64.
14. Foulks GN, Borchman D, Yappert M, et al. Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study. Cornea 2013;32:44-53.
15. Bahrami F, Morris DL, Pourgholami MH. Tetracyclines: drugs with huge therapeutic potential. Mini Rev Med Chem 2012;12:44-52.
16. Foulks GN, Borchman D, Yappert M, et al. Topical azithromycin therapy of meibomian gland dysfunction: clinical response and lipid alterations. Cornea 2010;29:781-8.
17. Bertino JS Jr. Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics. Clin Ophthalmol 2009;3:507-21.
18. Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003;22:640-50.
19. Opitz DL, Tyler KF. Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis. Clin Exp Optom 2011;94:200-6.
20. Yoo SE, Lee DC, Chang MH. The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction. Korean J Ophthalmol 2005;19:258-63.
21. Dougherty JM, McCulley JP, Silvany RE, et al. The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci. Invest Ophthalmol Vis Sci 1991;32:2970-5.
22. Greene JB, Jeng BH, Fintelmann RE, et al. Oral azithromycin for the treatment of meibomitis. JAMA Ophthalmol 2014;132:121-2.
23. Bakar Ö, Demirc¸ay Z, Gürbüz O. Therapeutic potential of azithromycin in rosacea. Int J Dermatol 2004;43:151-4.
24. Ellenberg SS, Temple R. Placebo-controlled trials and active-controlled trials in the evaluation of new treatments. Ann Intern Med 2000;133:464-70.